Cambridge Investment Research Advisors’s Kyntra Bio KYNB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-425	Closed	-$128K	–	3109
2022 Q1	$128K	Hold	425	–	–	﹤0.01%	2975
2021 Q4	$150K	Sell	425 -8	-2%	-$2.49K	﹤0.01%	2963
2021 Q3	$111K	Buy	+433	New	+$153K	﹤0.01%	2938
2021 Q2	–	Sell	-240	Closed	-$208K	–	3121
2021 Q1	$208K	Sell	240 -100	-29%	-$106K	﹤0.01%	2585
2020 Q4	$315K	Sell	340 -80	-19%	-$84.1K	﹤0.01%	2092
2020 Q3	$432K	Sell	420 -39	-8%	-$42K	﹤0.01%	1700
2020 Q2	$465K	Buy	459 +5	+1%	+$4.64K	﹤0.01%	1598
2020 Q1	$394K	Sell	454 -4	-0.9%	-$3.98K	﹤0.01%	1510
2019 Q4	$491K	Buy	458 +12	+3%	+$12.3K	﹤0.01%	1589
2019 Q3	$412K	Hold	446	–	–	﹤0.01%	1631
2019 Q2	$504K	Buy	+446	New	+$488K	﹤0.01%	1417

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cambridge Investment Research Advisors's KYNB Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of Kyntra Bio (KYNB) in Q2 2022, closing a stake of 425 shares — an estimated $128K sold.

Cambridge Investment Research Advisors first reported a position in KYNB in Q2 2019 and held it in 11 quarters. The position peaked at $504K in Q2 2019. 150 funds tracked by Wall St. Rank hold KYNB as of Q2 2022.

Cambridge Investment Research Advisors reported no remaining Kyntra Bio position as of Q2 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 425 Kyntra Bio shares in Q2 2022, an estimated $128K.
Cambridge Investment Research Advisors first reported a position in Kyntra Bio in Q2 2019 and held it in 11 quarters.
Cambridge Investment Research Advisors's Kyntra Bio position peaked at $504K in Q2 2019.
150 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.